NCT00120796View on ClinicalTrials.gov

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

PHASE3TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Hepatitis B

Interventions

DRUG

Lamivudine

BIOLOGICAL

Recombinant hepatitis B surface antigen

Trial Locations (1)

Unknown

Hopital Principal, Dakar

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV